TY  - GEN
AU  - Brown,A
AU  - Hézode,C
AU  - Zuckerman,E
AU  - Foster,G R
AU  - Zekry,A
AU  - Roberts,S K
AU  - Lahser,F
AU  - Durkan,C
AU  - Badshah,C
AU  - Zhang,B
AU  - Robertson,M
AU  - Wahl,J
AU  - Barr,E
AU  - Haber,B
TI  - Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study
SN  - 1365-2893
PY  - 2018///1015
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Amides
KW  - Antiviral Agents
KW  - administration & dosage
KW  - Benzofurans
KW  - Carbamates
KW  - Cyclopropanes
KW  - Drug Therapy, Combination
KW  - adverse effects
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - epidemiology
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - classification
KW  - Hepatitis C, Chronic
KW  - drug therapy
KW  - Humans
KW  - Imidazoles
KW  - Male
KW  - Middle Aged
KW  - Quinoxalines
KW  - Ribavirin
KW  - Sulfonamides
KW  - Sustained Virologic Response
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/jvh.12801
ER  -